US IVD (In Vitro Diagnostic) growth set to continue despite cost constraints
This article was originally published in Clinica
US demand for in vitro diagnostic (IVD) reagents and instrumentation will continue to grow at 6% a year to reach $10.5 billion by 2003. Cost-containment pressures will continue to force prices down and constrain demand, but this will be more than offset by the growth of the point-of-care and home testing markets. These are the conclusions of the Freedonia Group, a US industrial market research company.
You may also be interested in...
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.
A lower first dose boosted the vaccine’s efficacy result, but AstraZeneca has conceded that this has to be proven in a separate trial. In the meantime, the UK government has asked the regulator to assess the vaccine under a special health emergency provision.